LEGAL & MEDICAL DISCLAIMER: The information provided on this page by PeptideMatch.io is intended solely for educational and informational purposes. It does not constitute, and should not be interpreted as, professional medical advice, diagnosis, or treatment. Always consult a licensed physician or qualified healthcare provider before beginning any peptide therapy or making changes to an existing treatment plan. PeptideMatch.io does not prescribe, dispense, or endorse any specific therapeutic protocol. Individual results may vary, and no outcomes are guaranteed.

What Is Retatrutide?

If you follow the world of metabolic medicine, you’ve probably heard the buzz around retatrutide. It’s being called the most powerful weight-loss drug ever tested in a clinical trial, and the data, so far, backs that up. But retatrutide isn’t just another GLP-1 drug. It works in a fundamentally different way, and understanding that difference is what makes it genuinely interesting.

In the world of weight loss and metabolic health, glucagon was long considered the enemy, a hormone famous for raising blood sugar when the body needs energy. But in a surprising twist of pharmacology, scientists discovered that when you combine glucagon with two other appetite-suppressing hormones, it doesn’t just raise blood sugar; it forces the body to burn significantly more energy. That unexpected synergy is the driving force behind the most powerful experimental weight-loss peptide in development today.

Retatrutide (development code LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly and Company. It belongs to a new class of drugs called triple hormone receptor agonists, meaning it simultaneously activates three separate receptors: the GLP-1 receptor, the GIP receptor, and the glucagon receptor.¹

That third receptor is the key differentiator. Most people are now familiar with GLP-1 receptor agonists like semaglutide, and dual agonists like tirzepatide that also activate the GIP receptor. GIP, short for glucose-dependent insulinotropic polypeptide, is a second gut hormone released after meals; it enhances insulin secretion and influences how the body stores and uses fat. Retatrutide goes one step further by also engaging the glucagon receptor, a move that adds a powerful new mechanism to the mix: significantly increased energy expenditure.^1,2

Fast Facts

FULL NAME	Retatrutide (development code LY3437943)
CLASS	Triple hormone receptor agonist (GLP-1, GIP, and glucagon receptors)
PRIMARY ACTION	Suppresses appetite and increases energy expenditure by simultaneously activating three incretin receptors
ADMINISTRATION	Once-weekly subcutaneous injection
DEVELOPER	Eli Lilly and Company
RESEARCH	Phase 3 clinical trials ongoing as of April 2026
REGULATORY STATUS	Not approved by the FDA or any global regulatory body; available legally only through clinical trials as of April 2026

How Does Retatrutide Work?

Retatrutide is structurally similar to GIP, but its peptide backbone has been modified to allow it to bind and activate all three incretin receptors simultaneously. Incretins are gut hormones released after meals that tell the pancreas to release insulin and help regulate appetite and metabolism; drugs that mimic them are known collectively as incretin therapies. Think of retatrutide as a single key that opens three different locks, each one triggering a distinct metabolic effect.¹

1. GLP-1 Receptor Activation

Activating the GLP-1 receptor increases insulin secretion in response to meals, delays gastric emptying, and powerfully reduces appetite. This is the same mechanism that makes semaglutide effective, and it forms the foundation of retatrutide’s action.¹

2. GIP Receptor Activation

GIP receptor activation has been associated with enhanced insulin secretion, glucose uptake in peripheral tissues, and modulation of glucagon release. It also plays a role in fat metabolism. Adding GIP to GLP-1 is what differentiates tirzepatide from semaglutide, and retatrutide includes this component as well.²

3. Glucagon Receptor Activation, the Key Differentiator

The glucagon receptor component is what sets retatrutide apart from every other approved incretin therapy. Glucagon naturally raises blood sugar, which is why older glucagon-based approaches were considered risky in metabolic disease. Retatrutide’s innovation is balancing glucagon receptor activation against the powerful blood-sugar-lowering effects of GLP-1 and GIP. The result: significantly increased energy expenditure (the body burns more calories at rest) without the dangerous rise in blood sugar that limited earlier glucagon-based approaches.^1,2

What Does the Research Say?

The clinical evidence for retatrutide has been building steadily across Phase 2 and Phase 3 randomized controlled trials (RCTs), and the results have consistently surprised researchers.

PeptideMatch.io presents this data to help our community understand the scope of research and the distinction between early findings and confirmed outcomes.

THERAPEUTIC AREA	WHAT RESEARCH SUGGESTS	EVIDENCE LEVEL
Obesity	24.2% mean weight loss at 48 weeks (12 mg dose); no plateau observed3	Phase 2 RCT
Type II Diabetes	HbA1c reduction of 2.02% at 24 weeks; ~17% weight loss at 36 weeks4	Phase 2 RCT
Weight Loss/Pain	28.7% mean weight loss at 68 weeks (~71 lbs); significant knee pain reduction5	Phase 3 RCT
Liver Fat	86% of participants achieved normal liver fat at 24 weeks (12 mg dose)6	Phase 2a RCT
Rate of Weight Loss	Greatest weight loss across all incretin comparators in Bayesian network analysis7,8	Systematic Review

The TRIUMPH-4 Phase 3 result, 28.7% mean weight loss at 68 weeks, is the highest ever recorded in a randomized controlled trial for obesity. For context, semaglutide 2.4 mg (Wegovy) produces approximately 15% weight loss at 68 weeks, and tirzepatide produces approximately 21%.⁵

Weight Loss and Body Composition

Retatrutide’s defining benefit is the magnitude of weight loss it produces. By coupling appetite suppression (GLP-1 + GIP) with increased energy expenditure (glucagon), it achieves outcomes that exceed every previously studied incretin therapy in head-to-head comparison.^5,8

• Phase 3 TRIUMPH-4 Results: 28.7% mean weight loss at 68 weeks (~71 lbs), the highest ever recorded in an obesity randomized controlled trial.⁵

• No Observed Plateau: Phase 2 trials at the 12 mg dose showed weight loss continuing through week 48 with no apparent ceiling, suggesting room for additional reduction with longer treatment.³

• Best-in-Class Comparison: A 2025 Bayesian network meta-analysis of GLP-1, dual, and triple agonists found retatrutide produced the greatest weight loss across all incretin comparators.⁸

Important: Retatrutide remains investigational. Phase 3 TRIUMPH-OUTCOMES data on long-term cardiovascular outcomes are not expected until 2029, and the FDA has not approved retatrutide for any indication as of April 2026.

The same mechanisms that drive weight loss also produce significant secondary benefits across other metabolic measures, suggesting retatrutide may become useful for a broader range of conditions than obesity alone. In a Phase 2a trial of patients with metabolic dysfunction-associated steatotic liver disease (MASLD), 86% of participants on the 12 mg dose achieved normal liver fat levels after just 24 weeks, an outcome not previously reported with any other peptide therapy.⁶

Phase 2 trials in type 2 diabetes showed an HbA1c reduction of 2.02% at 24 weeks alongside roughly 17% weight loss at 36 weeks.⁴ The TRIUMPH-4 Phase 3 trial also reported significant knee pain reduction in patients with obesity-related osteoarthritis, a quality-of-life endpoint that reflects the broader systemic effects of substantial weight loss.⁵

Retatrutide’s safety profile across all trials has been broadly consistent with other incretin-based therapies. The most commonly reported adverse events are gastrointestinal, nausea, vomiting, diarrhea, and constipation, and are dose-dependent and typically transient, occurring most frequently during the dose-escalation phase.^2,3

One concern researchers monitored carefully was the potential for the glucagon component to cause a dangerous rise in blood sugar or ketoacidosis (a serious condition where the blood becomes too acidic). So far, no cases of ketoacidosis have been reported in any trial, and no liver damage from the drug has been identified, including in the MASLD substudy where liver disease was already present at the start.⁶ A 2025 systematic review confirmed an appropriate safety profile consistent with the incretin mimetic drug class.⁷

Important Considerations

Regulatory Status	Not approved by the FDA or any global regulatory body as of April 2026; available legally only through clinical trials.
Cardiovascular Outcomes	Long-term data from the TRIUMPH-OUTCOMES study (expected completion 2029) are still being collected.
Common Side Effects	Nausea, vomiting, diarrhea, and constipation, most common during dose escalation and typically resolve.
No Ketoacidosis Signal	Nausea, vomiting, diarrhea, and constipation, most common during dose escalation and typically resolve.
Medical Oversight	Always work with a licensed healthcare provider before considering any peptide therapy.

The Bottom Line: Retatrutide represents a real leap forward in the science of peptide therapy for metabolic health. By adding glucagon receptor agonism to the GLP-1 and GIP combination, it achieves weight loss numbers that were unimaginable just a few years ago, and its effects on liver fat, blood sugar, and body composition suggest it may become a cornerstone treatment for a wide range of metabolic conditions. That said, it is still investigational. Long-term cardiovascular outcomes data are pending, and FDA approval is likely still years away. If you’re interested in whether retatrutide or a comparable peptide therapy might be appropriate for your situation, the right first step is a conversation with a qualified clinician who specializes in metabolic medicine.

Scientific References

1. Ramsbacher N. Retatrutide. Clin Diabetes. 2024;42(4):579-580.
2. Doggrell SA. Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023;32(5):391-396.
3. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial. N Engl J Med. 2023;389(6):514-526.
4. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544.
5. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful phase 3 trial. Press release. December 11, 2025.
6. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037-2048.
7. Abdrabou Abouelmagd A, Abdelrehim AM, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Baylor Univ Med Cent Proc. 2025.
8. Sinha B, Ghosal S. Efficacy and safety of GLP-1 receptor agonists, dual agonists, and retatrutide for weight loss in adults with overweight or obesity: a Bayesian network meta-analysis. Obesity. 2025.

©2026 PeptideMatch.io. All Rights Reserved. This educational content is the exclusive intellectual property of PeptideMatch.io. Reproduction, distribution, republication, or transmission of this material, in whole or in part, in any form or by any means, is strictly prohibited without the prior written consent of PeptideMatch.io. For licensing or reprint inquiries, please contact content@peptidematch.io.